News & Updates

In the phase II NEOBLADE* trial, the addition of the multikinase** inhibitor nintedanib to neoadjuvant chemotherapy (CT) consisting of gemcitabine and cisplatin failed to improve pathological complete response (pCR) and progression-free survival (PFS) in individuals with locally advanced muscle-invasive bladder cancer (MIBC).

The anaplastic lymphoma kinase (ALK) inhibitor ceritinib delivers favourable antitumour activity in ALK-mutated nonsmall cell lung cancer (NSCLC) patients with active brain metastases and/or leptomeningeal disease, according to the phase II ASCEND-7 trial.

Patients with psoriatic arthritis (PsA) with no prior exposure to biological disease-modifying antirheumatic drugs (bDMARDs) experience improvements in their condition when treated with bimekizumab, according to results of the phase III BE OPTIMAL trial.

Treatment with vunakizumab, a novel interleukin 17A monoclonal antibody, shows promise for moderate-to-severe plaque psoriasis and good tolerability, according to the results of a recent study.

The use of antibiotic therapy to resolve chronic endometritis can put women undergoing assisted reproductive treatment (ART) at heightened risk of pregnancy loss, according to a study.

The ketogenic diet, as well as ketogenic agents, has been shown to be a promising therapeutic regimen for Parkinson’s disease (PD) in animals, but research on humans is highly heterogenous and lacking PD-specific outcomes, according to a study.